Suppr超能文献

美国乙肝病毒感染率及免疫率方面的种族/族裔差异。

Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States.

作者信息

Kim H S, Rotundo L, Yang J D, Kim D, Kothari N, Feurdean M, Ruhl C, Unalp-Arida A

机构信息

Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.

Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.

出版信息

J Viral Hepat. 2017 Nov;24(11):1052-1066. doi: 10.1111/jvh.12735. Epub 2017 Jul 3.

Abstract

Hepatitis B virus (HBV) infection in the United States is the most common among Asians followed by non-Hispanic blacks. However, there have been few studies that describe HBV infection and immunity by racial group. Our study aimed to assess racial/ethnic disparities in the prevalence and awareness of HBV infection and immunity using nationally representative data. In the National Health and Nutrition Examination Survey 2011-2014, 14 722 persons had HBV serology testing. We estimated the prevalence of HBV infection, past exposure, and immunity by selected characteristics and calculated adjusted odds ratios using survey-weighted generalized logistic regression. Awareness of infection and vaccination history was also investigated. The overall prevalence of chronic HBV infection, past exposure and vaccine-induced immunity was 0.34% [95%CI 0.24-0.43], 4.30% [95%CI 3.80-4.81], and 24.4% [95%CI 23.4-25.4], respectively. The prevalence of chronic infection was 2.74% [95% CI 1.72-3.76] in Asians, 0.64% [95% CI 0.35-0.92] in non-Hispanic blacks, and 0.15% [95% CI 0.06-0.24] in non-Asian, non-blacks. Only 26.2% of those with chronic infection were aware of their infection. The prevalence of the past exposure was 21.5% [95%CI 19.3-23.7] in Asians, 8.92% [95%CI 7.84-9.99] in non-Hispanic blacks, 2.05% [95%CI 1.49-2.63] in non-Hispanic whites and 4.47% [95%CI 3.25-5.70] in Hispanics. Prevalence of vaccine-induced immunity by each race was 34.1% [95%CI: 32.0-36.2] in Asians, 25.5% [95%CI: 24.0-27.0] in non-Hispanic blacks, 24.0% [95%CI: 22.6-25.4] in non-Hispanic whites and 22.2% [95%CI: 21.3-23.3] in Hispanics. There are considerable racial/ethnic disparities in HBV infection, exposure and immunity. More active and sophisticated healthcare policies on HBV management may be warranted.

摘要

在美国,乙型肝炎病毒(HBV)感染在亚洲人中最为常见,其次是非西班牙裔黑人。然而,很少有研究按种族群体描述HBV感染和免疫情况。我们的研究旨在利用全国代表性数据评估HBV感染和免疫在患病率及知晓率方面的种族/民族差异。在2011 - 2014年全国健康与营养检查调查中,14722人接受了HBV血清学检测。我们根据选定特征估计了HBV感染、既往接触史和免疫的患病率,并使用调查加权广义逻辑回归计算调整后的优势比。同时还调查了感染知晓情况和疫苗接种史。慢性HBV感染、既往接触史和疫苗诱导免疫的总体患病率分别为0.34% [95%置信区间0.24 - 0.43]、4.30% [95%置信区间3.80 - 4.81]和24.4% [95%置信区间23.4 - 25.4]。亚洲人中慢性感染的患病率为2.74% [95%置信区间1.72 - 3.76],非西班牙裔黑人中为0.64% [95%置信区间0.35 - 0.92],非亚洲非黑人中为0.15% [95%置信区间0.06 - 0.24]。只有26.2%的慢性感染者知晓自己的感染情况。既往接触史的患病率在亚洲人中为21.5% [95%置信区间19.3 - 23.7],非西班牙裔黑人中为8.92% [95%置信区间7.84 - 9.99],非西班牙裔白人中为2.05% [95%置信区间1.49 - 2.63],西班牙裔中为4.47% [95%置信区间3.25 - 5.70]。各种族疫苗诱导免疫的患病率在亚洲人中为34.1% [95%置信区间:32.0 - 36.2],非西班牙裔黑人中为25.5% [95%置信区间:24.0 - 27.0],非西班牙裔白人中为24.0% [95%置信区间:22.6 - 25.4],西班牙裔中为22.2% [95%置信区间:21.3 - 23.3]。HBV感染、接触和免疫方面存在相当大的种族/民族差异。可能需要制定更积极、完善的HBV管理医疗政策。

相似文献

1
Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States.
J Viral Hepat. 2017 Nov;24(11):1052-1066. doi: 10.1111/jvh.12735. Epub 2017 Jul 3.
2
Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey.
Ann Intern Med. 2011 Mar 1;154(5):319-28. doi: 10.7326/0003-4819-154-5-201103010-00006.
5
Prevalence of Undetectable Vaccine-Induced Immunity Against Hepatitis B Virus in US Adults at High Risk for Infection.
Hepatology. 2019 Apr;69(4):1385-1397. doi: 10.1002/hep.30285. Epub 2019 Feb 20.
6
Chronic Hepatitis B Prevalence Among Foreign-Born and U.S.-Born Adults in the United States, 1999-2016.
Hepatology. 2020 Feb;71(2):431-443. doi: 10.1002/hep.30831. Epub 2019 Aug 13.
8
The prevalence of hepatitis B virus infection in the United States in the era of vaccination.
J Infect Dis. 2010 Jul 15;202(2):192-201. doi: 10.1086/653622.
9
Seroprevalence of Hepatitis B Infection in Nigeria: A National Survey.
Am J Trop Med Hyg. 2016 Oct 5;95(4):902-907. doi: 10.4269/ajtmh.15-0874. Epub 2016 Aug 15.

引用本文的文献

1
Incidence trends and disparities in infection-related malignancies of the liver among US adults, 2000-2019.
Gastroenterol Rep (Oxf). 2025 Jun 16;13:goaf050. doi: 10.1093/gastro/goaf050. eCollection 2025.
3
Differences in Hepatocellular Carcinoma Incidence Trends Across US Census Divisions, 2001 to 2021.
Cancers (Basel). 2025 Apr 24;17(9):1431. doi: 10.3390/cancers17091431.
4
Association of Vaccination in Pregnancy With Newborn Hepatitis B Vaccine Receipt.
Perm J. 2025 Mar 14;29(1):84-88. doi: 10.7812/TPP/24.061. Epub 2025 Mar 5.
5
Shattering the monolith: burden of gastrointestinal cancer in Asian Americans, Native Hawaiians, and Pacific Islanders in the United States.
Lancet Reg Health Am. 2024 Nov 23;41:100954. doi: 10.1016/j.lana.2024.100954. eCollection 2025 Jan.
6
Health disparities in cirrhosis care and liver transplantation.
Nat Rev Gastroenterol Hepatol. 2025 Feb;22(2):98-111. doi: 10.1038/s41575-024-01003-1. Epub 2024 Oct 31.
7
The role of culturally appropriate interpersonal communication strategies to reduce hepatitis B and liver cancer disparities.
Front Public Health. 2024 Aug 9;12:1377096. doi: 10.3389/fpubh.2024.1377096. eCollection 2024.
8
Existing knowledge, myths, and perceptions about hepatitis B and liver cancer within highly impacted immigrant communities.
J Virus Erad. 2024 Jun 14;10(2):100379. doi: 10.1016/j.jve.2024.100379. eCollection 2024 Jun.
10
Chronic Hepatitis B in Women of Childbearing Age and Pregnant Women in China: A Cross-Sectional Study.
Am J Trop Med Hyg. 2024 Mar 5;110(4):719-723. doi: 10.4269/ajtmh.23-0217. Print 2024 Apr 3.

本文引用的文献

2
The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013.
Lancet. 2016 Sep 10;388(10049):1081-1088. doi: 10.1016/S0140-6736(16)30579-7. Epub 2016 Jul 7.
3
The global burden of viral hepatitis: better estimates to guide hepatitis elimination efforts.
Lancet. 2016 Sep 10;388(10049):1030-1031. doi: 10.1016/S0140-6736(16)31018-2. Epub 2016 Jul 7.
4
What Stands in the Way of Making Hepatitis B and C Rare Diseases in the United States?
Ann Intern Med. 2016 Aug 16;165(4):284-5. doi: 10.7326/M16-0772. Epub 2016 Apr 12.
5
Surveillance of Vaccination Coverage Among Adult Populations - United States, 2014.
MMWR Surveill Summ. 2016 Feb 5;65(1):1-36. doi: 10.15585/mmwr.ss6501a1.
6
Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.
J Infect Dis. 2016 Jul 1;214(1):16-22. doi: 10.1093/infdis/jiv748. Epub 2016 Jan 21.
7
AASLD guidelines for treatment of chronic hepatitis B.
Hepatology. 2016 Jan;63(1):261-83. doi: 10.1002/hep.28156. Epub 2015 Nov 13.
9
Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013.
Lancet. 2015 Oct 17;386(10003):1546-55. doi: 10.1016/S0140-6736(15)61412-X. Epub 2015 Jul 28.
10
Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey.
Aliment Pharmacol Ther. 2015 Jan;41(1):65-76. doi: 10.1111/apt.13012. Epub 2014 Nov 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验